Our ambition and strategic priorities
Vicore is unlocking the potential of a new class of drugs – Angiotensin II Type 2 Receptor Agonists (ATRAGs) – stopping disease progression and restoring function.
We have a strong history of collaboration with the scientific community, leading to a wealth of preclinical data and ongoing clinical research in multiple indications to prove the AT2 receptor biology. Patients motivate us to explore this protective resolution and repair system to address unmet medical needs and create value across multiple disease areas.
With our deep expertise in the area, and the extensive chemistry program generating novel ATRAGs with long patent life and improved properties, we are in a unique position to exploit these opportunities to bring novel therapies to patient populations with large unmet medical need.
Our near-term priorities include advancing C21 to late-stage development in IPF (Idiopathic Pulmonary Fibrosis) and realizing the DTx opportunity by completing the ongoing clinical study and commercializing Almee in anxiety related to pulmonary fibrosis.